<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177602</url>
  </required_header>
  <id_info>
    <org_study_id>TARC-01</org_study_id>
    <nct_id>NCT04177602</nct_id>
  </id_info>
  <brief_title>Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial</brief_title>
  <official_title>Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servier Affaires Médicales</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD)&#xD;
      of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1)&#xD;
      with an experimental arm with Trifluridine/tipiracil based chemoradiotherapy (CRT) and a&#xD;
      standard - calibration arm (internal control) with capecitabine CRT flanked by translational&#xD;
      research in patients with locally advanced rectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter randomized seamless phase I/II trial with a phase I for determination&#xD;
      of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II&#xD;
      trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil in&#xD;
      combination with standard radiotherapy and a standard - calibration arm (internal control)&#xD;
      with capecitabine CRT flanked by translational research, designed to assess the clinical&#xD;
      performance and efficacy of Trifluridine/tipiracil compared to current standard capecitabine&#xD;
      chemoradiation in patients with locally advanced rectal cancer.&#xD;
&#xD;
      The primary clinical objective in phase I is to determine the dosage and feasibility of&#xD;
      Trifluridine/tipiracil based chemoradiation and in phase II whether Trifluridine/tipiracil&#xD;
      with preoperative chemoradiation improves pathological complete remissions in patients with&#xD;
      locally advanced rectal cancer.&#xD;
&#xD;
      The secondary objectives are to evaluate Trifluridine/tipiracil chemoradiation with respect&#xD;
      to disease free survival, overall survival, local regional failure, pathological down-staging&#xD;
      (ypT0-2N0) rate, tumour regression grade, histopathological R0 resection rate, neoadjuvant&#xD;
      rectal score (NAR), and perioperative complication rate. Safety and toxicity, according to&#xD;
      NCI CTC AE v5, quality of life and feasibility of the regimen are further secondary&#xD;
      objectives that are to be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil based chemoradiotherapy (CRT) and a standard - calibration arm (internal control) with capecitabine CRT flanked by translational research</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)/Phase 1 part</measure>
    <time_frame>8 weeks</time_frame>
    <description>Toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of pathological complete remissions (pCR)/Phase 2 part</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>4 years</time_frame>
    <description>recurrence and survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional failure</measure>
    <time_frame>4 years</time_frame>
    <description>Loco-regional recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological R0 resection rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour regression grades</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological down-staging (ypT0-2N0) rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant rectal score (NAR)</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical stage and Pathohistological response (&lt;8 low, 8-16 intermediate, &gt;16 high risk)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of adverse events according to NCI CTC AE v5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of perioperative complications</measure>
    <time_frame>3 months</time_frame>
    <description>Perioperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Trifluridine/tipiracil based radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trifluridine/tipiracil based chemoradiotherapy (CRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard calibration arm (internal control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine based chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Trifluridine/tipiracil chemoradiation</intervention_name>
    <description>Trifluridine/tipiracil based chemoradiation</description>
    <arm_group_label>Trifluridine/tipiracil based radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Capecitabine based chemoradiation</intervention_name>
    <description>Capecitabine based chemoradiation</description>
    <arm_group_label>standard calibration arm (internal control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients with histologically proven adenocarcinoma of the rectum&#xD;
             (tumour ≤ 12 cm from the anal verge)&#xD;
&#xD;
          2. Indication for neoadjuvant chemoradiation: clinical tumour stage T3/4 or any&#xD;
             node-positive disease (clinical stage according the TNM classification system, based&#xD;
             on MRI).&#xD;
&#xD;
          3. No evidence of metastatic disease (as evidenced by negative CT-scan of the chest and&#xD;
             abdomen).&#xD;
&#xD;
          4. The disease must be considered either resectable at the time of entry or expected to&#xD;
             become resectable after preoperative chemoradiation.&#xD;
&#xD;
          5. Age ≥ 18 years&#xD;
&#xD;
          6. WHO/ECOG Performance Status ≤ 2&#xD;
&#xD;
          7. No prior cytotoxic chemotherapy or radiotherapy for rectal cancer.&#xD;
&#xD;
          8. No prior radiotherapy to the pelvis, for any reason.&#xD;
&#xD;
          9. Presence of adequate contraception in fertile patients. Adequate methods of&#xD;
             contraception are: intra-uterine device, hormonal contraception, condom use with&#xD;
             spermicide. Pregnant or breastfeeding women are excluded from participation.&#xD;
&#xD;
         10. Adequate bone marrow, hepatic and renal function: Haemoglobin ≥9.0 g/dL (transfusions&#xD;
             allowed to achieve or maintain levels), absolute neutrophil count ≥ 1.5 x 109/L,&#xD;
             platelet count ≥ 100 x 109/L, ALAT, ASAT ≤ 2.5 x ULN, Alkaline phosphatase ≤ 2.5 x&#xD;
             ULN, Total bilirubin ≤1.5 x ULN, Creatinine clearance &gt; 50 mL/min (calculated&#xD;
             according to Cockroft and Gault).&#xD;
&#xD;
         11. Ability to swallow tablets.&#xD;
&#xD;
         12. Written informed consent and patient's agreement to comply with the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous (within the last 3 years) or concurrent malignancies, with the exception of&#xD;
             adequately treated cone-biopsied in situ carcinoma of the cervix or basal cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
          2. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,&#xD;
             symptomatic coronary artery disease and cardiac arrhythmia not well controlled with&#xD;
             medication) or myocardial infarction within the last 12 months.&#xD;
&#xD;
          3. Known allergy or any other adverse reaction to any of the study drugs or to any&#xD;
             related compound.&#xD;
&#xD;
          4. Known significant impairment of intestinal resorption (e.g. chronic diarrhea,&#xD;
             inflammatory bowel disease).&#xD;
&#xD;
          5. Pre-existing condition which would deter chemoradiotherapy or radiotherapy, i.e.&#xD;
             fistulas, severe ulcerative colitis (particularly patients currently taking&#xD;
             sulphasalazine), Crohn's disease, prior adhesions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Stein</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cancer Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Stein</last_name>
    <phone>+49(0)403603522</phone>
    <phone_ext>0</phone_ext>
    <email>stein@hope-hamburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Sinn</last_name>
    <phone>+49(0)407410</phone>
    <phone_ext>0</phone_ext>
    <email>ma.sinn@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus Hospital</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, Prof</last_name>
      <phone>+49 461 816 2512</phone>
      <email>Nadezda.Basara@malteser.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lübecker Onkologische Schwerpunktpraxis Dres. med. Uthgenannt, Kirso, Weber</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kisro, Dr</last_name>
      <phone>+49 451 70797 226</phone>
      <email>jens.kisro@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Dr. Hancken / MVZ Onkologie</name>
      <address>
        <city>Stade</city>
        <state>Schleswig-Holstein</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Meiler, Dr</last_name>
      <phone>+49 4141 604 226</phone>
      <email>Johannes.meiler@hancken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Halle</name>
      <address>
        <city>Halle/Saale</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mascha Binder, Prof</last_name>
      <email>mascha.binder@uk-halle.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Reese</last_name>
      <email>thomas.reese@uk-halle.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hämatologisch- Onkologische Praxis Eppendorf (HOPE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eray Goekkurt, Dr</last_name>
      <phone>+49 40 36035 220</phone>
      <email>goekkurt@onkologie-eppendorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>II. Medizinische Klinik und Poliklinik Hubertus Wald Tumorzentrum - UCCH</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Sinn, Dr</last_name>
      <phone>+49(0)407410</phone>
      <phone_ext>70434</phone_ext>
      <email>ma.sinn@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Mueller</last_name>
      <phone>+49(0)7410</phone>
      <phone_ext>57725</phone_ext>
      <email>tho.mueller@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis für Innere Medizin Schwerpunkt Hämatologie, Onkologie und Palliativmedizin Dres. Verpoort, Wierecky &amp; Zeller</name>
      <address>
        <city>Hamburg</city>
        <zip>20259</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Wierecky, Dr</last_name>
      <phone>+49 40 3571777 0</phone>
      <email>wierecky@onkologie-hamburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologisch- Onkologische Praxis Altona (HOPA)</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunter Schuch, Dr</last_name>
      <phone>+49 40 380212 60</phone>
      <email>gunter.schuch@hopa-hamburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trifluridine tipiracil chemoradiation</keyword>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

